Aztreonam-Avibactam Dosing
For adults with normal renal function (CrCL >50 mL/min), administer aztreonam-avibactam 500/167 mg IV loading dose over 30 minutes, followed by 1500/500 mg IV every 6 hours as 3-hour infusions. This fixed 3:1 ratio regimen is optimized for joint pharmacodynamic target attainment and is supported by Phase 3 clinical trial data 1, 2, 3.
Adult Dosing by Renal Function
Normal Renal Function (CrCL >50 mL/min)
- Loading dose: 500/167 mg IV over 30 minutes
- Maintenance dose: 1500/500 mg IV every 6 hours as 3-hour infusions
- This regimen achieves >90% joint probability of target attainment (aztreonam 60% fT>8 mg/L and avibactam 50% fT>2.5 mg/L) 1, 2
Moderate Renal Impairment (CrCL 31-50 mL/min)
- Dose adjustment required based on creatinine clearance 1, 3
- The loading dose remains 500/167 mg IV over 30 minutes
- Maintenance doses are reduced proportionally to renal function
- Population pharmacokinetic modeling supports these adjustments to maintain therapeutic exposures while preventing accumulation 2
Severe Renal Impairment (CrCL 15-30 mL/min)
- Further dose reduction necessary 1
- Specific regimens were developed through iterative PK modeling
- Administer after careful assessment of creatinine clearance
End-Stage Renal Disease
- Dosing regimens have been evaluated through simulation studies 2
- Requires individualized dosing based on dialysis schedule and residual renal function
Pediatric Dosing
Current evidence does not provide specific pediatric dosing recommendations for aztreonam-avibactam. The available literature focuses exclusively on adult populations 1, 2, 3, 4.
For reference, standard aztreonam monotherapy in children is dosed at 90-120 mg/kg/day divided every 6-8 hours (maximum 8 g/day) 5. However, this cannot be directly extrapolated to the aztreonam-avibactam combination due to the fixed 3:1 ratio formulation and lack of pediatric pharmacokinetic data for avibactam.
Critical Dosing Considerations
Infusion Duration Matters
- The 3-hour infusion for maintenance doses is essential for achieving optimal pharmacodynamic targets 1, 2
- Shorter infusions result in inadequate time above MIC thresholds
- The loading dose uses a 30-minute infusion to rapidly achieve therapeutic concentrations
Fixed Ratio is Non-Negotiable
- The 3:1 aztreonam-to-avibactam ratio must be maintained 1, 2
- This ratio was specifically optimized through probability of target attainment analyses
- Avibactam exposure drives the joint PTA within clinically relevant ranges 1
Infection Type Impacts Exposure
- Patients with complicated intra-abdominal infections demonstrate lower drug exposures compared to other infection types 2
- Despite this, the approved regimen maintains adequate joint PTA (89% to >99%) across infection types
- No dose adjustment by infection type is recommended, but awareness of this variability is important
Common Pitfalls to Avoid
Do not use IDSA-recommended ceftazidime-avibactam plus aztreonam regimens as a substitute. These achieve joint PTA <85% due to insufficient avibactam exposures when using standard ceftazidime-avibactam dosing with separate aztreonam 2. The fixed-ratio aztreonam-avibactam formulation provides superior avibactam exposure.
Do not omit the loading dose. The 500/167 mg loading dose supports more rapid achievement of joint pharmacodynamic targets 1. Starting directly with maintenance doses delays therapeutic effect.
Do not round or adjust the 3:1 ratio. Earlier iterations using 500/137 mg loading and 1500/410 mg maintenance doses were abandoned because they provided suboptimal avibactam exposure 1, 3.
Metronidazole Co-Administration
For complicated intra-abdominal infections, add metronidazole 500 mg IV every 8 hours to provide anaerobic coverage 3, 4. Aztreonam-avibactam lacks activity against anaerobes.
Monitoring Requirements
- Assess renal function at baseline and regularly during therapy to ensure appropriate dose adjustments 2
- Creatinine clearance should be calculated, not estimated from serum creatinine alone
- Time-varying creatinine clearance significantly impacts both aztreonam and avibactam clearance 2